1. Home
  2. RZLT vs LUNG Comparison

RZLT vs LUNG Comparison

Compare RZLT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.99

Market Cap

420.8M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.95

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RZLT
LUNG
Founded
2010
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
420.8M
97.1M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
RZLT
LUNG
Price
$3.99
$1.95
Analyst Decision
Strong Buy
Buy
Analyst Count
6
7
Target Price
★ $9.67
$5.38
AVG Volume (30 Days)
★ 1.3M
284.9K
Earning Date
05-13-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.47
7.64
EPS
N/A
★ N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$1.07
$1.13
52 Week High
$11.46
$2.89

Technical Indicators

Market Signals
Indicator
RZLT
LUNG
Relative Strength Index (RSI) 40.49 43.64
Support Level $3.69 $1.20
Resistance Level $5.36 $2.16
Average True Range (ATR) 0.25 0.12
MACD -0.01 -0.02
Stochastic Oscillator 40.11 26.32

Price Performance

Historical Comparison
RZLT
LUNG

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: